PPSV23

BIOLOGICAL17 trials

Conditions

AsthmaCLLHealthyHealthy VolunteersPneumococcal DiseasePneumococcal InfectionPneumococcal InfectionsPneumococcal Infectious Disease

Phase 1

A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine

CompletedNCT03803202

GlaxoSmithKlineHealthy Volunteers, Pneumococcal Disease, Pneumonia, Bacterial

Start: 2019-01-24End: 2020-09-28Updated: 2023-12-21

A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants

CompletedNCT05827874

Janssen Research & Development, LLCHealthy

Start: 2023-04-12End: 2023-10-04Updated: 2025-03-04

Phase I Clinical Trial of PCV24 in People Aged 18 Years and Older

CompletedNCT06678607

Shanghai Reinovax Biologics Co.,LTDPneumococcal Infectious Disease

Start: 2023-11-19End: 2024-07-28Updated: 2024-11-07

Phase 2

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

CompletedNCT03313037

PfizerPneumococcal Infections

Start: 2017-10-10End: 2018-12-10Updated: 2019-12-26

Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine

Active, not recruitingNCT06678620

Shanghai Reinovax Biologics Co.,LTDPneumococcal Infectious Disease

Start: 2024-04-20End: 2026-03-31Target: 992Updated: 2025-12-17

Phase 3

Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults

CompletedNCT03760146

PfizerPneumococcal Disease

Start: 2018-12-12End: 2019-12-16Updated: 2021-12-02

Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination

CompletedNCT03835975

PfizerPneumococcal Disease

Start: 2019-02-12End: 2020-02-12Updated: 2021-02-21

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan

CompletedNCT04875533

PfizerPneumococcal Disease

Start: 2021-06-14End: 2022-05-13Updated: 2024-11-05

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

CompletedNCT05393037

Merck Sharp & Dohme LLCPneumococcal Disease

Start: 2022-07-13End: 2024-01-25Updated: 2026-02-05

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

CompletedNCT05420961

Merck Sharp & Dohme LLCPneumonia, Pneumococcal

Start: 2022-07-12End: 2023-05-16Updated: 2024-10-26

A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

CompletedNCT05464420

Merck Sharp & Dohme LLCPneumococcal Disease

Start: 2022-08-12End: 2023-05-25Updated: 2024-09-24

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)

CompletedNCT05569954

Merck Sharp & Dohme LLCPneumococcal Disease

Start: 2022-11-07End: 2025-02-07Updated: 2026-03-02

Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)

CompletedNCT05633992

Merck Sharp & Dohme LLCPneumococcal Disease

Start: 2023-01-10End: 2023-05-24Updated: 2024-10-02

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

CompletedNCT05696080

Merck Sharp & Dohme LLCPneumococcal Infection

Start: 2023-02-13End: 2024-02-16Updated: 2026-03-03

A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)

CompletedNCT06177912

Merck Sharp & Dohme LLCPneumococcal Infection

Start: 2024-01-18End: 2025-02-26Updated: 2026-03-11

Phase 4

Pneumococcal Vaccines in Patients With Asthma

CompletedNCT03260790

Mayo ClinicAsthma

Start: 2017-10-01End: 2020-12-25Updated: 2021-11-05

Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia

CompletedNCT05316831

Region Örebro CountyCLL, Vaccine Response

Start: 2019-01-01End: 2022-10-01Updated: 2023-03-30

2025-11-10

Safety, tolerability, and immunogenicity of an adult-specific pneumococcal conjugate vaccine, V116, in people living with HIV (STRIDE-7): a two-part, parallel-group, randomised, active comparator-controlled, international, phase 3 trial.

2025-09-12

A phase 3 randomized trial (STRIDE-9) to evaluate the safety, tolerability, and immunogenicity of V116, a population-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve Japanese adults ≥65 years of age.

2025-08-05

A phase 3, randomized trial to evaluate lot-to-lot consistency of V116, an adult-specific pneumococcal conjugate vaccine (STRIDE-4).

2025-06-20

A randomized, open-label study on the effect of nipocalimab on vaccine responses in healthy participants

Human Vaccines & Immunotherapeutics2025-04-156 citations

A Phase 3 Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Vaccine, Compared with PPSV23, in Adults ≥50 Years of Age (STRIDE-10)

Vaccines2025-03-222 citations

Revaccination with pneumococcal conjugate vaccine five years after primary immunization improves immunity in patients with chronic lymphocytic leukemia

Haematologica2025-03-061 citations

P-45. A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Investigational Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age with Increased Risk for Pneumococcal Disease

Open Forum Infectious Diseases2025-01-29

A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine–Experienced Adults 50 Years of Age or Older (STRIDE-6)

Clinical Infectious Diseases2024-07-3125 citations

A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan

Vaccine2024-01-2315 citations

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease

Human Vaccines & Immunotherapeutics2022-11-117 citations

Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years

Vaccine2022-06-0967 citations

Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years

Clinical Infectious Diseases2021-12-22152 citations

A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination.

2021-11-2549 citations

Matching-adjusted indirect comparison of pneumococcal vaccines V114 and PCV20.

2021-10-2713 citations

A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age

Human Vaccines & Immunotherapeutics2021-03-042 citations

A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States

Human Vaccines & Immunotherapeutics2021-02-0515 citations

1240. Persistence of Circulating Antibody Through 12 Months Following Vaccination With a 20-Valent Pneumococcal Conjugate Vaccine in Adults 60–64 Years of Age

Open Forum Infectious Diseases2020-10-012 citations

Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age

Clinical Infectious Diseases2020-07-22156 citations

PPSV23

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Phase 4

Related Papers